Recent News

• 08.04.2026 - Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
• 07.22.2026 - Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast
• 07.14.2026 - Beyond the Freezing Point: The Science of Biopharmaceutical Preservation
• 07.08.2026 - Azenta Completes Sale of B Medical Systems
• 07.01.2026 - Lab Chemical Relocation: Hidden Risks and How to Avoid Them
• 06.10.2026 - Why Biological Material Lab Relocation Requires Much More Than Boxes and a Moving Truck
• 05.21.2026 - Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report
• 05.05.2026 - Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029
• 04.29.2026 - Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast
• 04.07.2026 - Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution

Recent Filings

• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.04.2026 - 8-K Current report
• 08.04.2026 - EX-99.1 EX-99.1
• 07.08.2026 - 8-K Current report
• 07.08.2026 - EX-99.1 EX-99.1
• 05.26.2026 - SD Specialized disclosure report
• 05.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2026 - 4 Statement of changes in beneficial ownership of securities